Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q1 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $192 thousand versus the consensus estimate of $180 thousand.

For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.

Earnings